Validity and efficiency of progression-free survival (PFS)-2 as a surrogate endpoint for overall survival (OS) in advanced cancer.

作者
Rachel Woodford,Deborah Zhou,Peey‐Sei Kok,Sally Lord,Michael Friedländer,Ian C. Marschner,John Simes,Chee Khoon Lee
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:40 (16_suppl): 6518-6518 被引量:1
标识
DOI:10.1200/jco.2022.40.16_suppl.6518
摘要

6518 Background: PFS is used widely as a primary endpoint in oncology trials and as a surrogate for OS. PFS-2, defined as time from randomization to progression on second line therapy, is potentially a more reliable surrogate than PFS but requires additional follow-up time. We evaluated the validity and efficiency of PFS-2 as a surrogate endpoint for OS and compared its performance with PFS. Methods: We performed an electronic search to identify randomized trials of advanced solid tumors reporting on PFS, PFS-2 and OS as pre-specified endpoints. We compared the correlations in the relative treatment effect for OS with PFS and PFS-2. We extracted data from Kaplan-Meier survival curves to create individual patient data to estimate time to statistical significance (TSS), defined as logrank P < 0.05. We further computed the samples size (person-year follow-up) required to reach statistical significance and assessed for the effect of survival post-progression (SPP). If trials failed to reach statistical significance for a particular endpoint, the maximal follow-up time was used. Results: Our study consisted of 39 analysis units with 20714 patients. Correlations of the OS treatment effect with the PFS and PFS-2 treatment effects were r= 0.12 (95% CI 0.00-0.13) and r= 0.67 (95% CI 0.08-0.69) respectively. The median differences in TSS between OS with PFS, OS with PFS-2, and PFS2 with PFS were 8.7, 8.4, and 3.2 months respectively. For trials with a SPP < 12 months, smaller differences in the median TSS as compared to SPP ≥12 months were seen. The median differences in follow-up required to reach statistical significance were 329, 151 and 122 person-years (PY) respectively. These differences were equivalent to a median 18.3% increase in sample size required for PFS-2 over PFS. The median increase in sample sizes were 18.2% and 22.3% for trials with SPP < 12 and ≥12 months respectively. Conclusions: PFS-2 has a stronger correlation with OS benefit than PFS. When PFS-2 is used as primary endpoint, trials will require an additional median 3.2 months to achieve statistical significance, and an additional 18.3% increase of sample size over PFS. PFS-2 balances between improved correlation with OS but modest increase in follow-up time and sample size. PFS-2 should therefore be considered as a primary endpoint in future trials of advanced cancers.[Table: see text]

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
852的应助被Yaqi采纳,获得10
刚刚
深情哈密瓜完成签到,获得积分10
刚刚
奕柯完成签到,获得积分10
刚刚
嘎嘎嘎嘎完成签到,获得积分10
1秒前
程佑贵完成签到,获得积分20
1秒前
无限凛发布了新的文献求助10
1秒前
ljq0814完成签到 ,获得积分10
1秒前
天天向上的应助被无昵称采纳,获得10
1秒前
星空发布了新的文献求助10
1秒前
Zilong864完成签到,获得积分10
1秒前
ding的应助被时尚的无声采纳,获得10
1秒前
核桃的应助被哈哈哈采纳,获得30
1秒前
高高高高高一剑完成签到,获得积分10
2秒前
2秒前
2秒前
dadsafyf发布了新的文献求助10
2秒前
way完成签到,获得积分10
2秒前
平淡茈完成签到,获得积分10
3秒前
luoshiyi完成签到,获得积分10
3秒前
3秒前
疯狂加载ing完成签到,获得积分0
3秒前
3秒前
Shafrir完成签到,获得积分10
4秒前
malistm完成签到,获得积分10
4秒前
5秒前
5秒前
罗龙生完成签到,获得积分10
5秒前
5秒前
磨人的老妖精完成签到,获得积分0
5秒前
醉熏的灵完成签到,获得积分10
5秒前
5秒前
5秒前
安纳完成签到,获得积分10
6秒前
华仔的应助被田所浩二采纳,获得10
6秒前
6秒前
cdercder的应助被vicastle采纳,获得10
6秒前
wanci的应助被mgq采纳,获得10
6秒前
WangJ1018完成签到,获得积分10
6秒前
乐善好施八宝粥完成签到,获得积分10
6秒前
我爱科研发布了新的文献求助10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180488
求助须知:如何正确求助?哪些是违规求助? 9570485
关于积分的说明 21812623
捐赠科研通 7776592
什么是DOI,文献DOI怎么找? 3433286
关于科研通互助平台的介绍 2557522
邀请新用户注册赠送积分活动 2479162